Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
- Status
- UNKNOWN
- Phase
- PHASE2
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
- Status
- COMPLETED
- Phase
- N/A